|1.||Falini, Brunangelo: 32 articles (05/2015 - 03/2002)|
|2.||Mecucci, Cristina: 15 articles (05/2008 - 01/2005)|
|3.||Martelli, Maria Paola: 14 articles (05/2015 - 06/2006)|
|4.||Martelli, Massimo F: 13 articles (11/2010 - 01/2005)|
|5.||Falini, B: 12 articles (02/2015 - 02/2000)|
|6.||Liso, Arcangelo: 11 articles (01/2011 - 01/2005)|
|7.||Amin, Hesham M: 10 articles (09/2015 - 09/2003)|
|8.||Medeiros, L Jeffrey: 10 articles (12/2013 - 09/2003)|
|9.||Bolli, Niccolò: 10 articles (01/2011 - 04/2006)|
|10.||Lai, Raymond: 9 articles (04/2013 - 09/2003)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/01/2007 - "NPM1 gene mutations causing aberrant cytoplasmic localization of nucleophosmin have been demonstrated to be the most frequent submicroscopic alterations in cytogenetically normal acute myeloid leukemia and to confer improved prognosis, especially in patients without a concomitant FLT3 gene internal tandem duplication. "
03/01/2014 - "Mutations of the nucleophosmin (NPM1) gene are considered as the most frequent acute myeloid leukemia (AML)-associated genetic lesion, reported with various incidences in different studies, and type A (NPM1-A) is the most frequent type. "
04/01/2009 - "The aim of this study was to evaluate the nucleophosmin (NPM1) gene exon 12 mutation in patients with acute myelogenous leukemia (AML) and its clinical characteristics. "
01/01/2009 - "Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these mutations with a more favorable clinical outcome. "
06/01/2007 - "No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group."
08/28/2015 - "The nucleophosmin (NPM1) activates cancer development and progression in many malignant tumors. "
07/01/2015 - "The transcriptional factor MYC and the nucleophosphoprotein nucleophosmin (NPM) act in concert to regulate the proliferation of both normal and cancer cells. "
06/01/2015 - "Nucleophosmin (NPM)/B23, a multifunctional nucleolar phosphoprotein, plays an important role in ribosome biogenesis, cell cycle regulation, apoptosis and cancer pathogenesis. "
06/01/2015 - "GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer."
06/01/2015 - "Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology."
01/01/2014 - "In addition, blasts of patients with mutant nucleophosmin (NPM1) revealed significantly higher CD33 and CD123 expression pointing toward the possibility of minimal residual disease-guided interventions in mutated NPM1-positive AMLs. "
06/01/2007 - "Clinical research has revealed that NPM mutations are relative to prognosis and can be used to monitor and quantify minimal residual disease (MRD) in AML patients with normal karyotype, therefore, these findings indicate that nucleophosmin mutations might contribute to illustration of myeloid leukemogenesis. "
04/01/2009 - "A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations."
09/01/2008 - "Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression."
05/01/2007 - "To explore the validity and prognostic significance of minimal residual disease detection by quantitative polymerase chain reaction (qPCR) in patients of acute myeloid leukemia (AML) bearing Nucleophosmin (NPM1) mutations, we quantified mutants in 194 bone marrow samples from 38 patients with a median follow-up time of 20.6 months. "
02/01/2014 - "We focus AML with mutations of the Nucleophosmin gene (NPM1) and show evidence to suggest that wild-type NPM1 has an inhibitory influence on BRD4 that is relieved upon NPM1c mutation and cytosplasmic dislocation. "
02/01/2009 - "In this study, we provide evidence that aberrant cytoplasmic dislocation of nucleophosmin - the immunohistochemical surrogate for NPM1 mutations - allows the two entities to be genetically separated. "
05/01/2011 - "These mutations, termed NPM1c, result in cytoplasmic dislocation of nucleophosmin and are associated with distinctive transcriptional signatures, yet their role in leukemogenesis remains obscure. "
08/01/2010 - "Notably, NPM is mutated in about one third of acute myeloid leukaemia (AML) patients and these mutations lead to aberrant cytoplasmic dislocation of nucleophosmin (NPM-c). "
10/01/2009 - "Mutations of NPM1 gene leading to aberrant cytoplasmic dislocation of nucleophosmin (NPMc+) occurs in about one third of acute myeloid leukaemia (AML) patients that exhibit distinctive biological and clinical features. "
|5.||Wilms Tumor (Wilm's Tumor)
11/01/2012 - "Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression."
11/01/2012 - "We compared the clinical value of minimal residual disease (MRD) monitoring by cytofluorimetric methods, Wilms tumor gene 1 (WT1) expression and the study of nucleophosmin gene (NPM) mutations in a series of 26 patients with NPM-mutated de novo acute myeloid leukemia (NPM-AML) who achieved complete hematological remission after conventional chemotherapy. "
06/01/2012 - "Patients were also assessed for the presence of FLT3 (fms-like tyrosine kinase receptor-3), NPM1 (nucleophosmin), CEBPA, WT1 (Wilms tumor 1), IDH1 (isocitrate dehydrogenase 1) and IDH2 mutations. "
10/01/2011 - "We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy. "
08/01/2010 - "The review focuses on research advances abroad in this field including gene mutations suggesting bad prognosis such as FMS-related tyrosine kinase 3 gene mutation, Baalc gene and ETS-related gene hyperexpression, Wilms' tumor gene mutation and other gene mutations as well as gene mutations suggesting good prognosis such as nucleophosmin gene mutation, mixed lineage leukemia-partial tandem duplication, CCAAT/enhancer-binding protein α gene mutation."
|2.||anaplastic lymphoma kinase
|4.||tyrosine receptor (receptor, tyrosine)
|5.||fms-Like Tyrosine Kinase 3
|6.||DNA (Deoxyribonucleic Acid)
|7.||Small Interfering RNA (siRNA)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|9.||Proteins (Proteins, Gene)
|10.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)